证券代码：688356 证券简称：键凯科技 公告编号：2025-037 北京键凯科技股份有限公司 股东询价转让计划书 股东 XUAN ZHAO（以下简称"出让方"）保证向北京键凯科技股份有限 公司（以下简称"键凯科技"）提供的信息内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其真实性、准确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 拟参与键凯科技首发前股东询价转让（以下简称"本次询价转让"）的 股东为 XUAN ZHAO； 出让方拟转让股份的总数为 1,819,521 股，占键凯科技总股本的比例为 3%； 管理人员，持有键凯科技股份比例超过 5%。 （三）出让方关于拟转让股份权属清晰、不存在限制或者禁止转让情形、 不存在违反相关规则及其作出的承诺的声明 本次询价转让不通过集中竞价交易或大宗交易方式进行，不属于通过二 级市场减持。受让方通过询价转让受让的股份，在受让后 6 个月内不得转让； 本次询价转让的受让方为具备相应定价能力和风险承受能力的机构投资 者。 一、拟参与转让的股东情况 （一）出让方的名称、持股数量、持股比例 出让方委托 ...

（北京市朝阳区安立路 66 号 4 号楼） 中信建投证券股份有限公司 关于北京键凯科技股份有限公司 股东向特定机构投资者询价转让股份 相关资格的核查意见 1 中信建投证券股份有限公司（以下简称"中信建投证券"）受北京键凯科技 股份有限公司（以下简称"键凯科技"）股东 XUAN ZHAO（以下简称"出让方"） 委托，组织实施本次键凯科技首发前股东向特定机构投资者询价转让（以下简称 "本次询价转让"）。 根据《关于在上海证券交易所设立科创板并试点注册制的实施意见》《科创 板上市公司持续监管办法（试行）》《上海证券交易所科创板股票上市规则》《上 海证券交易所科创板上市公司自律监管指引第 4 号——询价转让和配售》（以下 简称"《询价转让和配售指引》"）等相关规定，中信建投证券对参与本次询价转 让股东的相关资格进行核查，并出具本核查意见。 一、 本次询价转让的委托 中信建投证券收到出让方关于本次询价转让的委托，委托中信建投证券组织 实施本次询价转让。 二、 关于参与本次询价转让股东相关资格的核查情况 （一） 核查过程 根据相关法规要求，中信建投证券对出让方的相关资格进行了核查。出让方 已出具《关于向特定机构投资者询价 ...

智通财经APP讯，键凯科技(688356.SH)披露股东询价转让计划书，拟参与本次询价转让的股东为XUAN ZHAO，拟转让股份的总数为181.95万股，占公司总股本的比例为3%。 ...

键凯科技公告，股东XUAN ZHAO拟通过询价转让方式转让181.95万股，占公司总股本的3%。此次转让 不通过集中竞价交易或大宗交易进行，受让方为具备相应定价能力和风险承受能力的机构投资者，且受 让后6个月内不得转让。 ...

Core Viewpoint - JianKai Technology's stock price has shown significant volatility, with a year-to-date increase of 60.22%, but a recent decline in the last five trading days by 1.88% [2] Group 1: Stock Performance - As of November 11, JianKai Technology's stock price rose by 2.01% to 90.99 CNY per share, with a market capitalization of 5.519 billion CNY [1] - The stock has experienced a 6.11% increase over the past 20 days, while it has decreased by 9.19% over the last 60 days [2] - The company has appeared on the "Dragon and Tiger List" once this year, with a net buy of 39.1731 million CNY on July 21 [2] Group 2: Financial Performance - For the period from January to September 2025, JianKai Technology reported a revenue of 211 million CNY, reflecting a year-on-year growth of 13.47% [2] - The net profit attributable to the parent company for the same period was 40.7246 million CNY, marking a year-on-year increase of 24.72% [2] - Cumulatively, the company has distributed 178 million CNY in dividends since its A-share listing, with 99.8755 million CNY distributed over the last three years [3] Group 3: Shareholder Information - As of September 30, 2025, JianKai Technology had 6,608 shareholders, an increase of 23.19% from the previous period [2] - The average number of circulating shares per shareholder decreased by 18.83% to 9,178 shares [2] - Notably, CITIC JianKang A (002408) has exited the list of the top ten circulating shareholders [3]

证券代码：688356 证券简称：键凯科技 北京键凯科技股份有限公司 2025 年第二次临时股东会会议资料 2025 年 11 月 北京键凯科技股份有限公司 2025 年第二次临时股东会会议资料 目录 | 北京键凯科技股份有限公司 2025 年第二次临时股东会会议须知 3 | | --- | | 2025 年第二次临时股东会会议议程 6 | | 议案一：《关于变更公司 2025 年度审计机构的议案》 8 | | 议案二：《关于选举公司第四届董事会非独立董事的议案》 9 | | 议案三：《关于选举公司第四届董事会独立董事的议案》 10 | | 附件 1：非独立董事候选人简历 11 | | 附件 2：独立董事候选人简历 14 | 2 北京键凯科技股份有限公司 2025 年第二次临时股东会会议资料 北京键凯科技股份有限公司 2025 年第二次临时股东会会议须知 为维护全体股东的合法权益，确保股东会会议秩序和议事效率，保证股东会 的顺利召开，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、中国证监会《上市公司股东会规则》 以及《北京键凯科技股份有限公司章程 ...

Core Viewpoint - JianKai Technology (688356.SH) reported its Q3 2025 results, highlighting a decrease in institutional ownership and the presence of several public funds [1] Institutional Ownership - As of October 30, 2025, four institutional investors disclosed holdings in JianKai Technology, totaling 3.5961 million shares, which represents 5.93% of the company's total share capital [1] - The institutional ownership decreased by 1.67 percentage points compared to the previous quarter [1] Public Fund Disclosure - In this reporting period, 51 public funds were not disclosed compared to the previous quarter, including notable funds such as CITIC JianTou Medical Reform A, Oriental Red Medical Upgrade Stock Initiation A, and others [1]

Core Insights - JianKai Technology is a leading enterprise in the domestic polyethylene glycol modifier industry, focusing on the research, production, and sales of medical polyethylene glycol and its active derivatives [1] Financial Performance - For Q3 2025, JianKai Technology reported revenue of 211 million yuan, ranking 43rd in the industry, significantly lower than the top competitor, Puluo Pharmaceutical, which had 7.764 billion yuan [2] - The net profit for the same period was 40.72 million yuan, placing the company 28th in the industry, again below the leading firms [2] Profitability and Debt Management - The company's debt-to-asset ratio stood at 5.92% in Q3 2025, an increase from 5.49% year-on-year, which is substantially lower than the industry average of 27.75% [3] - The gross profit margin for Q3 2025 was 65.17%, down from 67.91% year-on-year, but still above the industry average of 35.38% [3] Leadership and Compensation - Chairman Zhao Xuan's compensation for 2024 was 1.4901 million yuan, a decrease of 78,100 yuan from 2023 [4] Shareholder Dynamics - As of September 30, 2025, the number of A-share shareholders increased by 23.19% to 6,608, while the average number of shares held per shareholder decreased by 18.83% [5] - The company is undergoing a performance transformation, with increased R&D investment of 42.6034 million yuan in H1 2025, a 52.44% increase year-on-year [5]

Core Viewpoint - The company, JianKai Technology, announced the convening of its board meeting to elect new directors, including independent and non-independent candidates, in accordance with relevant laws and regulations [1] Group 1 - The board of JianKai Technology consists of 9 directors, including 3 independent directors [1] - The third session of the board's 14th meeting will be held on October 30, 2025, to discuss the election of the fourth board's candidates [1] - The proposals for the nomination of both non-independent and independent directors were approved during the meeting [1]

Core Viewpoint - JianKai Technology (688356.SH) reported a year-on-year increase in revenue and net profit for the first three quarters of 2025, indicating positive growth trends in its financial performance [1] Financial Performance - The total operating revenue for the first three quarters reached 211 million yuan, representing a year-on-year growth of 13.47% [1] - The net profit attributable to shareholders of the parent company was 40.72 million yuan, showing a year-on-year increase of 24.72% [1] - The basic earnings per share stood at 0.67 yuan [1]